Products & Services · Probability of success factor
HLD-0117 — Probability of success factor
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityVolatile
First reportedQ4 2025
Last reportedQ4 2025Feb 11, 2026
How to read this metric
An increase indicates higher confidence in clinical or regulatory outcomes, leading to a higher valuation of the asset. A decrease reflects setbacks in trials or regulatory hurdles, signaling potential impairment or reduced future revenue expectations.
Detailed definition
The estimated statistical likelihood that the HLD-0117 development program will successfully navigate clinical trials an...
Peer comparison
Standard industry practice for biotech and pharma companies to apply probability-of-success (POS) adjustments to risk-adjusted net present value (rNPV) models for pipeline assets.
Metric ID:
jnj_segment_hld_0117_probability_of_success_factorHistorical Data
1 periods
| Q4 '25 | |
|---|---|
| Value | $0.17 |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's hld-0117 — probability of success factor?
- Johnson & Johnson (JNJ) reported hld-0117 — probability of success factor of $0.17 in Q4 2025.
- What does hld-0117 — probability of success factor mean?
- The percentage chance that the HLD-0117 drug will successfully reach the market.